Status:
COMPLETED
Action of Amantadine on Post-Stroke Aphasic Patients
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Cerebral Infarction
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
The objective of the study is to test the action of the amantadine, as DOPA-agonist, in a double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic post stroke aphasic pati...
Detailed Description
In France, there are around 30000 aphasic patients. The actual taking care of these patients after stroke includes the treatment of acute stage in stroke unit, followed by rehabilitation program. Howe...
Eligibility Criteria
Inclusion
- RANKIN \< 3
- \> 18 years and \< 75
- francophone
- within cognitive deficit known before stroke
- stroke, single in sylvian artery area
- aphasia " non fluent " following a stroke
- stroke \> six month
- stable treatment
Exclusion
- RANKIN \> 3
- non francophone
- do not read nor write
- many stroke - against indication
- participated in another clinical trial
- deaf or blind
- intercurrent disease
- new treatment (\< 2 months) cognitive
- pregnant or lactating
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00821691
Start Date
March 1 2009
End Date
April 1 2013
Last Update
April 21 2014
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Saint Pierre La Réunion
Saint-Pierre, Ile de La Réunion, France
2
University hospital of Bordeaux
Bordeaux, France
3
CHU de Dijon
Dijon, France
4
CHU Limoges
Limoges, France